SNORD114-17: A Potential Drug Target and Biomarker (G767595)

Target Name: SNORD114-17

NCBI ID: G767595

SNORD114-17

Other Name(s): small nucleolar RNA, C/D box 114-17 | Small nucleolar RNA, C/D box 114-17 | 14q(II-17)

SNORD114-17: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to interact with mRNAs to ensure their stability and translation efficiency. C/ D box 114-17 is a specific snRNA molecule that has been identified as a potential drug target and biomarker.

The C/D box 114-17 is a 24-nt RNA molecule that is located between the AUG and the start of the second exon of the gene SNORD114-17. It has a conserved structure that is composed of a stem-loop and a loop region. The stem-loop region has three'-terminal uracil(U) and a 5'-terminal methylprimer(P), while the loop region has a single U at the 2'-end and a second U at the 5' -end.

Recent studies have identified several potential functions for C/D box 114-17. One of the key functions of this RNA molecule is to interact with the mRNAs that it is associated with. This interaction is thought to play a role in the stability and translation efficiency of the mRNAs.

Another function of C/D box 114-17 is that it can act as a negative regulator of gene expression. This is because the stem-loop region of the RNA molecule contains a loop that can bind to the 3'-end of the mRNA . This interaction can inhibit the translation of the mRNA, which can lead to decreased levels of the protein encoded by the gene.

In addition to its role as a negative regulator, C/D box 114-17 has also been shown to play a role in the regulation of cellular processes. For example, studies have shown that C/D box 114-17 is involved in the regulation of cell cycle progression and the G1/S transition.

Given the significant role that C/D box 114-17 plays in the regulation of gene expression, it is a promising target for drug development. Many small molecules have been shown to interact with this RNA molecule, and several of these compounds have been shown to have potential therapeutic activity.

One of the most promising small molecules that has been shown to interact with C/D box 114-17 is called NKG26. NKG26 is a compound that was shown to inhibit the translation of the mRNA encoding the protein EIF4E, which is involved in the regulation of cellular processes such as cell cycle progression and the G1/S transition.

In addition to its potential therapeutic activity, NKG26 has also been shown to have a number of potential drug-like properties. For example, it has a stable structure and a low toxicity, which are both desirable characteristics for a drug.

Another small molecule that has been shown to interact with C/D box 114-17 is called FK506. FK506 is an immunosuppressant drug that is used to prevent the rejection of transplanted organs. 17 and to inhibit the translation of the mRNA encoding the protein Ovl1.

In addition to its potential therapeutic activity, FK506 has also been shown to have a number of potential drug-like properties. For example, it has a stable structure and a low toxicity, which are both desirable characteristics for a drug.

Overall, C/D box 114-17 is a promising target for drug development due to its role as a negative regulator of gene expression and its potential therapeutic activity. Further research is needed to fully understand the functions of this RNA molecule and to develop safe and effective drugs that can target it.

Protein Name: Small Nucleolar RNA, C/D Box 114-17

The "SNORD114-17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets